Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
27.01
+0.30 (1.12%)
Mar 4, 2026, 11:40 AM EST - Market open

Immunovant Balance Sheet

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Cash & Equivalents
994.53713.97635.37376.53493.82400.15
Cash & Short-Term Investments
994.53713.97635.37376.53493.82400.15
Cash Growth
165.43%12.37%68.74%-23.75%23.41%297.87%
Accounts Receivable
1.642.085.340.712.230.6
Other Current Assets
46.7751.7125.0727.16.898.26
Total Current Assets
1,043767.76665.77404.33512.93409.01
Net Property, Plant & Equipment
0.530.840.61.512.633.48
Other Long-Term Assets
8.927.62----
Total Assets
1,052776.22666.37405.84515.56412.49
Accounts Payable
8.6217.667.161.3518.632.43
Accrued Expenses
57.6451.1241.340.4224.5815.16
Current Portion of Leases
--0.141.171.151.18
Other Current Liabilities
--0.020.350.17-
Total Current Liabilities
66.2668.7848.6143.344.5218.77
Long-Term Leases
---0.051.222.24
Total Long-Term Liabilities
---0.051.222.24
Total Liabilities
66.2668.7848.6143.3445.7421.01
Common Stock
0.020.020.010.010.010.01
Additional Paid-in Capital
2,5821,9451,442927.98824.8590.43
Accumulated Other Comprehensive Income
1.21.461.910.850.4-0.3
Retained Earnings
-1,597-1,240-825.68-566.35-355.39-198.66
Shareholders' Equity
986.14707.45617.76362.49469.83391.48
Total Liabilities & Equity
1,052776.22666.37405.84515.56412.49
Total Debt
-00.141.222.363.42
Net Cash (Debt)
994.53713.97635.23375.31491.45396.73
Net Cash Growth
39.30%12.40%69.25%-23.63%23.88%294.48%
Net Cash Per Share
5.744.714.603.054.484.52
Book Value
986.14707.45617.76362.49469.83391.48
Book Value Per Share
5.694.674.472.954.284.46
Tangible Book Value
986.14707.45617.76362.49469.83391.48
Tangible Book Value Per Share
5.694.674.472.954.284.46
Updated Feb 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q